CSAM-SCAM Fundamentals. Cocaine Basics. Presentation provided by David C. Marsh MD CCSAM

Size: px
Start display at page:

Download "CSAM-SCAM Fundamentals. Cocaine Basics. Presentation provided by David C. Marsh MD CCSAM"

Transcription

1 CSAM-SCAM Fundamentals Cocaine Basics Presentation provided by David C. Marsh MD CCSAM

2

3 Chronic Illness Relapsing & Remitting in Course Genetic Predisposition Individual Choice a Factor Environmental Influence Potentially Fatal If Untreated Prevention Is Possible Properly Managed Can Lead Normal Life

4 Response Rates Drug and Alcohol Treatment 40-60% abstinent at 1 year (vary with drug) Best outcomes in those maintained in MMT or Participating in on-going Mutual Support Diabetes, Hypertension, Asthma 40-60% medication compliance <30% adherence with diet and risk reduction 50% symptoms require medical intervention within 1 year McLellan, Lewis, O Brien and Kleber (2000) JAMA 284:

5 Cocaine Effects Blocks Catecholamine Reuptake Dopamine, Noradrenalin, Adrenaline Euphoria Increased Energy Insomnia Anorexia Hypertension and Tachycardia Often combined with Alcohol to Prolong Effect

6 Cocaine Problems Multiple Organ Systems Damaged By Restriction of Blood Flow and Increased Metabolic Demand Myocardial Infarct or Arrhythmias Multiple Small Cerebral Infarcts Frequently Increased Sexual Risk Behaviour Risks Associated with Route of Use Smoking/Snorting Respiratory Damage Blood-Borne Illnesses passed by Sharing Implements Injection Local Sequelae including Infections Systemic Infections (Bacterial, Fungal, Viral)

7

8

9

10

11

12 # correct in 45 sec Stroop Task Improvement During Methamphetamine Abstinence Control (n = 141) * < 72 h n = 86 3 Months n = 19 *p < 0.05

13 Depression In Methamphetamine Abusers BDI Score Control scores = Weeks of Abstinence

14 Time (msec) % Correct Methamphetamine Abusers Show Impaired Attention * Reaction Time Accuracy *p<0.05

15 Cingulate Cortex In Methamphetamine Abuse Anterior Cingulate Posterior Cingulate

16 Glucose Metabolism (mg/100 g/min) Reaction Time Correlated To Angular Gyrus Metabolism In Methamphetamine Abusers CONTROL METHAMPHETAMINE r = r = 0.92 p < 0.05 Reaction Time (msec)

17 Emergency Management of Intoxication Stabilize Vital Signs (ABC s) Rule Out or Treat General Medical Conditions Diabetic Coma Subdural Haematoma Seizures Pneumonia Meningitis GI Bleeding

18 Subacute Management of Intoxication Provide a Reality Base Use names often State location repeatedly Non-Verbal Support Frequent, brief eye contact Relaxed posture Constant Subdued Lighting Never leave alone Always Check for Pregnancy Opiate Withdrawal in pregnancy can precipitate miscarriage

19 Pharmacological Treatment of Withdrawal (General Approaches) Symptomatic relief Cross-tolerance with longer half-life agent Less reinforcing and less dangerous mode of delivery of drug

20 Withdrawal Management and Treatment Treatment of Withdrawal is Not Treatment Patients with Substance Dependence requiring withdrawal management all require treatment Outpatient Counseling Intensive Day Treatment Intensive Residential Treatment Short-Term Residential Transitional Treatment Long-Term Residential Treatment Supportive Housing

21 Pharmacotherapy For Continuing Care (Broad Strategies) Pharmacological Avenues Aversion Decreased Appetite Decreased Reinforcement and Extinction Relapse Prevention Antagonist maintenance Long Acting Agonist Maintenance Prevent Complications In Face of Use

22 Oral Amphetamine Maintenance for Cocaine Dependence Pilot Study for 14 weeks (16 Pts. 60 mg/day; 14 Placebo) Treatment retention was equivalent between group Cocaine-positive urine samples treatment group declined from 94% to 56% compared no change in the placebo group (79% positive). treatment group reduced self-reported cocaine use (P= 0.02) reduced criminal activity (P=0.04) reduced cravings (P<0.01) reduced severity of cocaine dependence (P<0.01) no within-group improvements found in the placebo group Shearer J et al (2003) Addiction 98:

23 Pilot Studies of Medications for Cocaine Dependence in Heroin-Assisted Treatment Nuijten et al (2011) BMC Psychiatry 11:135

24 Topirimate for Cocaine Dependence Poor compliance with medication Limited benefit Nuijten et al (2015) Drug Alc Dep 138:177

25 Modafinil for Cocaine Dependence Poor compliance with medication Limited benefit unless high adherence Nuijten et al (2015) J Psychopharmacol 29:678

26 Fundamentals: Cannabis Dependence Summary Cocaine is highly reinforcing Dependence can be devastating to function but most users do not progress to dependence Treatment is challenging Relies on Psychosocial Interventions Medications should be primarily within context of clinical trials until proven effective

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs

More information

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?

More information

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives

More information

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine

Opioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene

More information

The causes of misuse:

The causes of misuse: The Drug Misuse The causes of misuse: Availability of drugs. A vulnerable personality. Adverse social environment. Regular drug taking play a role. Determining misuse and dependence, it is unclear whether

More information

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.

More information

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008 Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality

More information

Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users.

Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. Slide #1 Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale AIDS Program Medical Director South Central Rehabilitation

More information

THE STATE OF MEDICINE IN ADDICTION RECOVERY

THE STATE OF MEDICINE IN ADDICTION RECOVERY OVERVIEW: Review addiction stats and trends Define addiction Explain neurobiology of addiction Review treatments of addiction Addiction Definition: A Primary, chronic, relapsing disease of brain reward,

More information

The future of pharmacological treatment.

The future of pharmacological treatment. The future of pharmacological treatment. Anne Lingford-Hughes Professor of Addiction Biology, Imperial College. Hon Consultant CNWL NHS Foundation Trust. What substances and when? What Nicotine Alcohol

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

Polysubstance Use & Medication-Assisted Treatment

Polysubstance Use & Medication-Assisted Treatment Polysubstance Use & Medication-Assisted Treatment DSM-V eliminated polysubstance disorder, instead specifying each drug of abuse and dependence. Substance-use disorder is a combination of the two DSM-IV

More information

NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018

NALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018 NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications

More information

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States

More information

MARRCH Minnesota Society of Addiction Medicine Presents. Addiction as a Brain Disease

MARRCH Minnesota Society of Addiction Medicine Presents. Addiction as a Brain Disease MARRCH 2008 Minnesota Society of Addiction Medicine Presents Addiction as a Brain Disease Gavin Bart, MD Charles Reznikoff, MD Steven Fu, MD, MSCE David Frenz, MD, MS October 22, 2008 Schedule 10:00-12:00

More information

TREATMENT OF NICOTINE DEPENDENCE

TREATMENT OF NICOTINE DEPENDENCE TREATMENT OF NICOTINE DEPENDENCE Introduction Most commonly used substance the world over. Largest cause of preventable death worldwide. Leading causes of smoking related death Cardiovascular diseases

More information

Pharmacotherapy for Substance Use Disorders

Pharmacotherapy for Substance Use Disorders Pharmacotherapy for Substance Use Disorders Vanessa de la Cruz, MD Chief of Psychiatry Mental Health and Substance Abuse Services Santa Cruz County Health Services Agency 1400 Emeline Avenue Santa Cruz,

More information

Opioid dependence: Detoxification

Opioid dependence: Detoxification Opioid dependence: Detoxification What is detoxification? A. Process of removal of toxins from the body? B. Admitting a drug dependent person in a hospital and giving him nutrition? C. Stopping drug use

More information

Addiction as a Neuropsychiatric Medical Condition

Addiction as a Neuropsychiatric Medical Condition Addiction as a Neuropsychiatric Medical Condition Wilson M. Compton, M.D., M.P.E. Director, Division of Epidemiology, Services and Prevention Research National Institute on Drug Abuse 5 November 2009 Summary

More information

BASIC VOLUME. Elements of Drug Dependence Treatment

BASIC VOLUME. Elements of Drug Dependence Treatment BASIC VOLUME Elements of Drug Dependence Treatment Module 3 Principles of CBT and relapse prevention strategies Introduction to Cognitive Behavioural Therapy Basics of pharmacological treatment Workshop

More information

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

Substitution Therapy for Opioid Use Disorder The Role of Suboxone Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM

More information

Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP

Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP Disclosures This speaker has no conflicts of interest to disclose Objectives Define drug abuse and addiction Identify the

More information

Noel Schenk MD. Davis Behavioral Health

Noel Schenk MD. Davis Behavioral Health Noel Schenk MD Davis Behavioral Health Michael Botticelli Director of National Drug Control Policy What is Addiction? Addiction is defined as a chronic, relapsing brain disease that is characterized by

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC

Medications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are

More information

Management Options for Opioid Dependence:

Management Options for Opioid Dependence: Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice

More information

Models of good practice in drug treatment in Europe. Project group

Models of good practice in drug treatment in Europe. Project group Models of good practice in drug treatment in Europe ( moretreat 2006329 ) Project group Hamburg, London, Rome, Stockholm, Vienna, Warsaw, Zurich Project duration: 17 months from April 2006 August 2008

More information

Methamphetamine Abuse During Pregnancy

Methamphetamine Abuse During Pregnancy Methamphetamine Abuse During Pregnancy Robert Davis, MD / r.w.davismd@gmail.com ❶ Statistics ❷ Pregnancy Concerns ❸ Postpartum Concerns ❹ Basic Science ❺ Best Practice Guidelines ❻ Withdrawal ❼ Recovery

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Medication-Assisted Treatment. What Is It and Why Do We Use It? Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite

More information

Prescription Opioid Addiction

Prescription Opioid Addiction CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett

More information

Methamphetamine & Cocaine Use Disorders

Methamphetamine & Cocaine Use Disorders Methamphetamine & Cocaine Use Disorders Timothy E. Wilens, MD Director, Center for Addiction Medicine Chief, Division of Child and Adolescent Psychiatry, Massachusetts General Hospital Harvard Medical

More information

Brief Intervention for Smoking Cessation. National Training Programme

Brief Intervention for Smoking Cessation. National Training Programme Brief Intervention for Smoking Cessation National Training Programme Introduction Monitor tobacco use and prevention policies Protect people from tobacco smoke Offer help to quit tobacco use Warn about

More information

Update on Medications for Tobacco Cessation

Update on Medications for Tobacco Cessation Update on Medications for Tobacco Cessation Marc Fishman MD Johns Hopkins University Dept of Psychiatry Maryland Treatment Centers Baltimore MD MDQuit Best Practices Conference Jan 2013 Nicotine Addiction

More information

The Importance of Psychological Treatment and Behavioral Support

The Importance of Psychological Treatment and Behavioral Support The Importance of Psychological Treatment and Behavioral Support Michael W. Otto, PhD Department of Psychological and Brain Science Boston University Conflicts and Acknowledgements No industry funding

More information

Addiction Overview. Diane A. Rothon MD. Causes Consequences Treatments. Methadone/Buprenorphine 101 April 1, 2017

Addiction Overview. Diane A. Rothon MD. Causes Consequences Treatments. Methadone/Buprenorphine 101 April 1, 2017 Addiction Overview Causes Consequences Treatments Methadone/Buprenorphine 101 April 1, 2017 Diane A. Rothon MD Why? would you listen to this presentation Review the definition and neurobiology of addiction

More information

SW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass

SW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full

More information

Building capacity for a CHC response to Ontario's Opioid Crisis

Building capacity for a CHC response to Ontario's Opioid Crisis Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC

More information

Methamphetamine & Cocaine Use Disorders

Methamphetamine & Cocaine Use Disorders Methamphetamine & Cocaine Use Disorders Timothy E. Wilens, MD Director, Center for Addiction Medicine Chief, Division of Child and Adolescent Psychiatry, Massachusetts General Hospital Harvard Medical

More information

Medication-Assisted Treatment (MAT) Overview

Medication-Assisted Treatment (MAT) Overview Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for

More information

Medication Assisted Treatment of Substance Use Disorders

Medication Assisted Treatment of Substance Use Disorders 3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard

More information

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary

More information

What are Substance Use Disorders?

What are Substance Use Disorders? What are Substance Use Disorders? Sanchit Maruti, MD Michael Goedde, MD University of Vermont Medical Center 1 Disclosures } Drs. Maruti and Goedde receive compensation as consultants to the American Academy

More information

LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE

LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL

More information

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least

More information

Breaking the Chains of Nicotine Dependence - A Breakthrough Approach

Breaking the Chains of Nicotine Dependence - A Breakthrough Approach Breaking the Chains of Nicotine Dependence - A Breakthrough Approach Dr Rob Young Senior Lecturer & Consultant Physician Auckland Hospital, New Zealand Smoking Cessation in 2001 Smoking contributes to

More information

Methamphetamine & Cocaine Use Disorders

Methamphetamine & Cocaine Use Disorders Methamphetamine & Cocaine Use Disorders Timothy E. Wilens, MD Director, Center for Addiction Medicine Chief, Division of Child and Adolescent Psychiatry, Massachusetts General Hospital Harvard Medical

More information

Does the Use of Oral Amphetamines Reduce Cocaine Use in Cocaine-Dependent Individuals?

Does the Use of Oral Amphetamines Reduce Cocaine Use in Cocaine-Dependent Individuals? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Does the Use of Oral Amphetamines Reduce

More information

Buprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17

Buprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient

More information

Biological Addictions Treatment. Psychology 470. Many Types of Approaches

Biological Addictions Treatment. Psychology 470. Many Types of Approaches Many Types of Approaches Biological Addictions Treatment Psychology 470 Introduction to Chemical Additions Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Detoxification approaches

More information

DRUGS, ALCOHOL & MENTAL HEALTH, HOW THEY CONNECT

DRUGS, ALCOHOL & MENTAL HEALTH, HOW THEY CONNECT DRUGS, ALCOHOL & MENTAL HEALTH, HOW THEY CONNECT Robert Graham, Staff Specialist in Addiction Medicine (with thanks to Dr Thao Lam and Pip Bowden) Drug Health, Western Sydney Local Health District Robert.Graham@health.nsw.gov.au

More information

Understanding Addiction: Why Can t Those Affected Just Say No?

Understanding Addiction: Why Can t Those Affected Just Say No? Understanding Addiction: Why Can t Those Affected Just Say No? 1 The Stigma of Addiction There continues to be a stigma surrounding addiction even among health care workers. Consider the negative opinions

More information

Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP

Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Overview Gavin Foundation Injectable naltrexone Community report

More information

Understanding Addiction and Its Impact on the Brain. SDSMA Webinar Matthew Stanley, DO

Understanding Addiction and Its Impact on the Brain. SDSMA Webinar Matthew Stanley, DO Understanding Addiction and Its Impact on the Brain SDSMA Webinar Matthew Stanley, DO Estimated Economic Cost to Society Due to Substance Abuse and Addiction: Illegal drugs: Alcohol: Tobacco: $181 billion/year

More information

OPIOID ADDICTION AND THE BRAIN MICHAEL NERNEY AND ASSOCIATES P.O. BOX 93 LONG LAKE, NY

OPIOID ADDICTION AND THE BRAIN MICHAEL NERNEY AND ASSOCIATES P.O. BOX 93 LONG LAKE, NY OPIOID ADDICTION AND THE BRAIN MICHAEL NERNEY AND ASSOCIATES P.O. BOX 93 LONG LAKE, NY 12847-0093 518-624-5351 MCNERNEYLL@FRONTIERNET.NET A DISEASE OF THE BRAIN ASAM Primary chronic disease of the brain

More information

TREATMENT OF STIMULANT USE DISORDERS

TREATMENT OF STIMULANT USE DISORDERS Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences TREATMENT OF STIMULANT USE DISORDERS Matt Iles-Shih, MD Addiction Psychiatry Fellow University Of Washington & VA

More information

Quality assurance in pharmacotherapy with methadone

Quality assurance in pharmacotherapy with methadone Quality assurance in pharmacotherapy with methadone Dr. Emilis Subata Vilnius Centre for Addictive Disorders Psychiatry Clinic of Vilnius University emilis.subata@vplc.lt Outline of the presentation Introduction

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

Intro to Concurrent Disorders

Intro to Concurrent Disorders CSAM-SCAM Fundamentals Intro to Concurrent Disorders Presentation provided by Jennifer Brasch, MD, FRCPC Psychiatrist, Concurrent Disorders Program, St. Joseph s Healthcare There are all kinds of addicts,

More information

Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services

Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services www.randallwebber.com MAT clients are still addicted Truth: MAT clients will experience withdrawal symptoms if they stop

More information

Trigger. Myths About the Use of Medication in Recovery BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS

Trigger. Myths About the Use of Medication in Recovery BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module VI Counseling Buprenorphine Patients Myths About the Use of Medication in Recovery! Patients are still addicted!

More information

Vivitrol Vs. Suboxone

Vivitrol Vs. Suboxone Vivitrol Vs. Suboxone Vivitrol - Naltrexone Indicated for opiate dependence and alcohol withdrawal pure antagonist 380mg once every 4 weeks IM Peak plasma concentration in 2 hrs, followed by a second peak

More information

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment

Medication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin

More information

Page 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk

Page 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk Pharmacologic Interventions for Addictions Eric C. Strain, M.D. Johns Hopkins University School of Medicine, Baltimore, Maryland Maryland Psychiatric Society November 7, 2015 Objectives for This Talk I.

More information

Pharmacologic Interventions for. Addictions

Pharmacologic Interventions for. Addictions Pharmacologic Interventions for Addictions Eric C. Strain, M.D. Johns Hopkins University School of Medicine, Baltimore, Maryland Maryland Psychiatric Society November 7, 2015 Objectives for This Talk I.

More information

Management of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013

Management of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 Management of high risk MMT patients Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 CFPC CoI Templates: Slide 1 Faculty Disclosure Faculty: Meldon Kahan Relationships with commercial

More information

Opioids and Opioid Addiction: Practical Management Approaches

Opioids and Opioid Addiction: Practical Management Approaches Opioids and Opioid Addiction: Practical Management Approaches Yngvild Olsen, MD, MPH Medical Director Institutes for Behavior Resources Inc/REACH Health Services Conflict of Interest No financial or advisory

More information

Long term treatment for opioid dependence Antagonist therapy

Long term treatment for opioid dependence Antagonist therapy Long term treatment for opioid dependence Antagonist therapy Treatment of Opioid Dependence Antagonist treatment Naltrexone Naltrexone (NTX) synthesized in 1965 Eliminate drug carving and prevent relapse

More information

Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations

Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations Dr. Ajeet Sidana Department of Psychiatry Government Medical College & Hospital Chandigarh Scope of Presentation

More information

ADHD and Substance Use Disorders: An Intoxicating Combination

ADHD and Substance Use Disorders: An Intoxicating Combination ADHD and Substance Use Disorders: An Intoxicating Combination Timothy E. Wilens, MD Chief, Division of Child & Adolescent Psychiatry Director, Center for Addiction Medicine Massachusetts General Hospital

More information

THE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA

THE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA THE OPIOID CRISIS DEFINING THE CRISIS KATHLEEN DUPPER, MD MEDICAL DIRECTOR, HUNTSVILLE RECOVERY 19 th Annual Perinatal Conference: The Opioid Crisis September 21, 2018 DEFINING THE CRISIS NUMBER OF OPIOID-RELATED

More information

Evidence-Based Practice: Psychosocial Interventions

Evidence-Based Practice: Psychosocial Interventions Evidence-Based Practice: Psychosocial Interventions Maxine Stitzer, Ph.D. Johns Hopkins Univ SOM NIDA Blending Conference June 3, 2008 Cincinnati, Ohio Talk Outline What is an evidence-based practice?

More information

Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs

Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs CCHS/University of Alabama School of Medicine Assessment History

More information

ROSC & MAT II: Opioid Treatment Services

ROSC & MAT II: Opioid Treatment Services ROSC & MAT II: Opioid Treatment Services September 23, 2015 Stan DeKemper Executive Director Indiana Credentialing Association on Addiction and Drug Abuse 1 GOALS Review medication assisted recovery Identify

More information

National Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says

National Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says National Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says Last Updated February 2016 https://www.drugabuse.gov 1 Table of Contents Understanding Drug Abuse and Addiction:

More information

TOOL 1: QUESTIONS BY ASAM DIMENSIONS

TOOL 1: QUESTIONS BY ASAM DIMENSIONS TOOL 1: QUESTIONS BY ASAM DIMENSIONS The following tool highlights specific questions that should be asked of the patient for each ASAM dimension. Name Date of Birth Date of Interview Address Referred

More information

8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy

8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy Medication Assisted Treatment for Substance Abuse in Primary Care Dan Vinson August 1, 2013 1 The Big change in addiction medicine? These diseases are rapidly becoming medical diseases. Done are the days

More information

Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry

Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over

More information

Buprenorphine as a Treatment Option for Opioid Use Disorder

Buprenorphine as a Treatment Option for Opioid Use Disorder Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital

More information

Exploring Barriers & Solutions in Facilitating Detox

Exploring Barriers & Solutions in Facilitating Detox Exploring Barriers & Solutions in Facilitating Detox Dr Brion Sweeney 8 th April 2008 Background Everyone is an expert Abstinence Based Programmes Harm Reduction Approaches Remissions, Relapses and Interventions

More information

9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare

9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare Buprenorphine Treatment (Suboxone) Selahattin Kurter, MD Spectrum Healthcare Board Certified in Psychiatry and Addiction Medicine Disclosures No financial reimbursement for this lecture Consultant for

More information

Substance Use Disorders. A Major Problem. Defining Addiction 2/24/2009. Lifetime rates of alcoholism estimated at 13.4 %

Substance Use Disorders. A Major Problem. Defining Addiction 2/24/2009. Lifetime rates of alcoholism estimated at 13.4 % Substance Use Disorders A Major Problem Lifetime rates of alcoholism estimated at 13.4 % Rates of drug abuse estimated at 6% Marijuana is most frequent Approximately 600,000 deaths each year from substance

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

The role of behavioral interventions in buprenorphine treatment of opioid use disorders

The role of behavioral interventions in buprenorphine treatment of opioid use disorders The role of behavioral interventions in buprenorphine treatment of opioid use disorders Roger D. Weiss, MD Harvard Medical School, Boston, MA, McLean Hospital, Belmont, MA, USA Today s talk Review of studies

More information

Opioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA

Opioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical

More information

The Sinclair Method (TSM) for the Treatment of Alcoholism. Clinical Research Findings and Best Protocol for Success Updated 2014

The Sinclair Method (TSM) for the Treatment of Alcoholism. Clinical Research Findings and Best Protocol for Success Updated 2014 Information for Medical & Treatment Professionals The Sinclair Method (TSM) for the Treatment of Alcoholism Clinical Research Findings and Best Protocol for Success Updated 2014 "One medication, naltrexone,

More information

Many drugs of abuse are illegal drugs. Possessing, using, buying, or selling these drugs is illegal for people of any age.

Many drugs of abuse are illegal drugs. Possessing, using, buying, or selling these drugs is illegal for people of any age. 1 Chapter 12 Section 1 Objectives List six ways illegal drug use can be dangerous. State five reasons a person might try illegal drugs. Identify the reason drug abuse is especially dangerous to teens.

More information

Improving Outcomes in Methadone Treatment

Improving Outcomes in Methadone Treatment Improving Outcomes in Methadone Treatment Cognitive/Behavioral Treatment Contingency Management Michael J. McCann, MA Matrix Institute on Addictions COMP Symposium September 11, 2007 Overview of Presentation

More information

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)

More information

Treatment Alternatives for Substance Use Disorders

Treatment Alternatives for Substance Use Disorders Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict

More information

Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations

Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President

More information

Medical Interventions for Addiction in Primary Care Settings. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale University School of Medicine

Medical Interventions for Addiction in Primary Care Settings. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale University School of Medicine Medical Interventions for Addiction in Primary Care Settings R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale University School of Medicine March 23, 2010 NIH Consensus on Drug Treatment Drug Addiction

More information

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders

2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA Professor of Psychiatry,

More information

Treatment of Methamphetamine Dependence: Does Treatment Work?

Treatment of Methamphetamine Dependence: Does Treatment Work? Treatment of Methamphetamine Dependence: Does Treatment Work? Mary Lynn Brecht, Ph.D. Richard A. Rawson, Ph.D Semel Institute for Neuroscience and Human Behavior David Geffen School of Medicine University

More information

6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder

6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of

More information

The National Methamphetamine Symposium

The National Methamphetamine Symposium The National Methamphetamine Symposium Making Research Work in Practice 12 May 2015 Arts Centre, Melbourne Physical and psychological effects of methamphetamine use Amanda Baker PhD National Centre for

More information

Mary Ann Ferguson,Pharmacist St Josephs Health Care Concurrent Disorders Inpatient Unit

Mary Ann Ferguson,Pharmacist St Josephs Health Care Concurrent Disorders Inpatient Unit Mary Ann Ferguson,Pharmacist St Josephs Health Care Concurrent Disorders Inpatient Unit Fergusom@stjoes.ca Medication should be considered as part of the treatment plan for addictions/substance use disorders:

More information

Adult 65D-30 Intervention ASAM Level.05 DIMENSIONS Circle all items in each dimension that apply to the client. ADMISSION CRITERIA

Adult 65D-30 Intervention ASAM Level.05 DIMENSIONS Circle all items in each dimension that apply to the client. ADMISSION CRITERIA Adult 65D-30 Intervention ASAM Level.05 ADMISSION CRITERIA Place a check in the yes or no box that indicates validation or lack ASAM Requirements Withdrawal and of validation for placement into this level

More information

Medical Management of Substance Use Disorders: Does research translate to clinical practice

Medical Management of Substance Use Disorders: Does research translate to clinical practice Medical Management of Substance Use Disorders: Does research translate to clinical practice Ashwin A Patkar, MD Professor of Psychiatry & Community & Family Medicine Duke University Medical Center Durham,

More information

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Objectives 1. Discuss the effects of opiate addiction on mothers and infants. 2. Discuss a Medical Home

More information